课题基金 / 基金详情

Predictive biomarkers for ovarian cancer: analysis of patient derived xenografts under treatment at single cell resolution

Predictive biomarkers for ovarian cancer: analysis of patient derived xenografts under treatment at single cell resolution
卵巢癌的预测生物标志物：以单细胞分辨率分析接受治疗的患者来源的异种移植物
批准号：
454606
负责人：
Kabeer Farhia
金额：
$9.83万
依托单位：
BC Cancer, part of PHSA (Vancouver)
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-10-01 至 2024-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=454606&lang=en
关键词：
Chemotherapy Resistance High Grade Serous Cancer Humanized Mice Immunotherapy New Novel Combinations Ovarian Cancer Patient Derived Xenograft Models Patient'S Surgical Samples Pre And Post Treatment Genomic/Transcriptotmic Changes Single Cancer C

项目摘要

项目成果

Kabeer Farhia的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cancer cells become resistant to drugs via a natural selection process similar to antibiotic resistance. Learning how to rationally combine treatments to avoid drug resistance is a challenge. High grade serous ovarian cancer (HGSOC) is an example of a dif
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterization of lung-colonizing cells with tumor-initiating properties from mouse breast.
  • 批准号：
    263442
  • 项目类别：
  • 资助金额：
    $0.07万
  • 财政年份：
    2012
  • 负责人：
    Kabeer Farhia
  • 依托单位：
    McGill University
海外基金